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Background: Cardiovascular disease is associated with major morbidity and mortality in women in the Western
world. Prediction of an individual cardiovascular disease risk in young women is difficult. It is known that women
with hypertensive pregnancy complications have an increased risk for developing cardiovascular disease in later life
and pregnancy might be used as a cardiovascular stress test to identify women who are at high risk for
cardiovascular disease. In this study we assess the possibility of long term cardiovascular risk prediction in women
with a history of hypertensive pregnancy disorders at term.
Methods: In a longitudinal follow-up study, between June 2008 and November 2010, 300 women with a history of
hypertensive pregnancy disorders at term (HTP cohort) and 94 women with a history of normotensive pregnancies
at term (NTP cohort) were included. From the cardiovascular risk status that was known two years after index
pregnancy we calculated individual (extrapolated) 10-and 30-year cardiovascular event risks using four different risk
prediction models including the Framingham risk score, the SCORE score and the Reynolds risk score. Continuous
data were analyzed using the Student’s T test and Mann–Whitney U test and categorical data by the Chi-squared
test. A poisson regression analysis was performed to calculate the incidence risk ratios and corresponding 95%
confidence intervals for the different cardiovascular risk estimation categories.
Results: After a mean follow-up of 2.5 years, HTP women had significantly higher mean (SD) extrapolated 10-year
cardiovascular event risks (HTP 7.2% (3.7); NTP 4.4% (1.9) (p<.001, IRR 5.8, 95% CI 1.9 to 19)) and 30-year
cardiovascular event risks (HTP 11% (7.6); NTP 7.3% (3.5) (p<.001, IRR 2.7, 95% CI 1.6 to 4.5)) as compared to NTP
women calculated by the Framingham risk scores. The SCORE score and the Reynolds risk score showed similar
significant results.
Conclusions: Women with a history of gestational hypertension or preeclampsia at term have higher predicted
(extrapolated) 10-year and 30-year cardiovascular event risks as compared to women with a history of
uncomplicated pregnancies. Further large prospective studies have to evaluate whether hypertensive pregnancy
disorders have to be included as an independent variable in cardiovascular risk prediction models for women.
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Cardiovascular disease is associated with major morbid-
ity and mortality in women in the Western world [1].
Women are less likely to receive appropriate cardiovas-
cular preventive care compared to men and heart
disease in women is not always recognized as a major
health care concern [2]. Several epidemiological studies
have demonstrated the association between hypertensive
pregnancy disorders and cardiovascular morbidity and
mortality in later life [3-9]. Subsequently, it has been
suggested that pregnancy may act as an early natural
“stress test” unmasking underlying defects and thereby
identifying women at high risk for cardiovascular disease
in later life [10].
Worldwide, different risk prediction models have been
developed for individual risk prediction of cardiovascular
disease in both apparently healthy men and women
[11-17]. Currently, the Framingham risk score is the
most compared score in literature and widely used in
North American countries [18], while the systematic
coronary risk evaluation (SCORE) score has been ad-
vised by the European guidelines [19]. In spite of the ex-
istence and use of several risk prediction models, it
remains a great challenge to determine which specific
woman is at high risk for cardiovascular disease, espe-
cially in young women.
Obstetric history, e.g. hypertensive pregnancy disor-
ders, is not included as a variable in cardiovascular risk
prediction models. However, obstetric history may help
to identify women, who are at high risk for cardiovascu-
lar disease in later life; they may benefit from early
cardiovascular risk screening after their complicated
pregnancy together with subsequent individual cardio-
vascular risk prediction and primary prevention pro-
grams [20,21]. Mosca et al. showed that women, who
perceive themselves at risk for cardiovascular disease
and know the goals for prevention, are motivated to take
action toward a heart healthy life style [2,22].
In the present study, we assess cardiovascular event
risks in women with a history of gestational hyperten-
sion or preeclampsia at term using four previous de-
scribed validated cardiovascular risk prediction models,
including the 10-year Framingham risk score, the 30-
year Framingham risk score, the 10-year estimation by
the SCORE score, and the 10-year estimation by the
Reynolds risk score. According to the European cardio-
vascular risk factor management guidelines for young
women with elevated risk factor levels [23], we extrapo-
late the 10-year cardiovascular disease risks as if the
woman is 60 years old. The aim of this study is to com-
pare these estimated (extrapolated) 10-year and 30-year
cardiovascular disease risks between women with a
history of term gestational hypertension or term
preeclampsia and women with a history of termnormotensive pregnancies, in order to improve assess-
ment of reliable cardiovascular risk estimation for the




We studied 300 women who had delivered in the
Netherlands between 2005 and 2008, with the diagnosis
term gestational hypertension or term preeclampsia after
36 weeks' gestation and 94 healthy control women after
uncomplicated term pregnancies. The women were in-
vited for participation in the current follow-up study on
cardiovascular event risk estimation.
We enrolled women with a history of term gestational
hypertension or term preeclampsia from the Hyperten-
sion and Pre-eclampsia Intervention Trial At Term (the
HYPITAT study) [24]. Control women were friends of
the patients or women from midwifery practices from
three different locations in the Netherlands (Groningen,
Leiden and The Hague) and they were required to have
only previous uncomplicated normotensive pregnancies.
A detailed description of all inclusion and exclusion cri-
teria was previously published elsewhere [25,26] Exclu-
sion criteria for participation in the HYPITAT trial and
the follow-up study included: antihypertensive medica-
tion use for chronic hypertension, diabetes mellitus, ges-
tational diabetes treated with insulin, renal disease, heart
disease, previous caesarean section, hemolysis elevated
liver enzymes and low platelets syndrome (HELLP),
oliguria of less than 500 mL per 24 hours, pulmonary
edema or cyanosis, human immunodeficiency virus (HIV),
use of intravenous antihypertensive medication, fetal
anomalies, intrauterine growth restriction (IUGR), and ab-
normal fetal- heart rate monitoring. Exclusion criteria for
the NTP cohort included HELLP, gestational hyperten-
sion, preeclampsia, pre-existing hypertension, (gestational)
diabetes, premature delivery, delivery of a neonate with
intra uterine growth restriction (below the 5th percentile),
renal disease, heart disease, and HIV.
Pregnant and lactating women (within the last three
months) were excluded from the follow-up study.
The study was approved by the Institutional Review
Board of the University of Leiden (HYPITAT: P04.210)
and locally approved by the hospital board of the partici-
pating hospitals.
Definitions
Gestational hypertension was defined as diastolic blood
pressure of 95 mmHg or higher measured on two occa-
sions at least six hours apart. Preeclampsia was defined
as diastolic blood pressure of 90 mmHg or higher mea-
sured on two occasions at least six hours apart, com-
bined with proteinuria (two or more occurrences of
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24 hours urine collection, or ratio of protein to creatin-
ine > 30 mg/mmol). Severe gestational hypertension or
severe preeclampsia were defined as either systolic blood
pressure of 170 mmHg or higher, diastolic blood pres-
sure of 110 mmHg or higher, or proteinuria of 5 gram
or higher per 24 hours.
Hypertension at follow-up was defined as systolic
blood pressure ≥ 140 mmHg, or a diastolic blood pres-
sure ≥ 90 mmHg or current use of antihypertensive
medication.
Classic cardiovascular risk factor assessment
A detailed description of the cardiovascular risk factor
assessment and laboratory procedures has been pub-
lished elsewhere [25]. In short, after enrolment all par-
ticipants were invited for cardiovascular risk factor
assessment. After written informed consent they were
asked to complete a questionnaire including questions
about their medical history, current medication use, ob-
stetric history, subsequent pregnancy after index preg-
nancy and family history, including cardiovascular
disease. Cardiovascular risk factor assessment included:
blood pressure measurement, height and weight (with
calculated body mass index (BMI)), and fasting venous
blood sample drawing, assayed for: glucose, HDL
cholesterol, triglycerides and (high sensitive) C-reactive
protein.
Individual cardiovascular risk prediction
For the prediction of the 10-year general cardiovascular
disease risk by the Framingham risk score, cardiovascu-
lar risk factors were used according to the methodology
reported by D’Agostino et al. [27], i.e. age, total choles-
terol, HDL cholesterol, systolic blood pressure, treat-
ment for hypertension, and smoking. 10-Year general
cardiovascular disease was defined as coronary death,
myocardial infarction, coronary insufficiency, angina, is-
chemic stroke, hemorrhagic stroke, transient ischemic
attack, peripheral artery disease, and heart failure.
30-Year full cardiovascular disease estimation by the
Framingham risk score was calculated using the algo-
rithm reported by Pencina et al. [15] 30-Year full
cardiovascular disease was defined as coronary death,
myocardial infarction, fatal and non-fatal stroke, coron-
ary insufficiency, angina pectoris, transient ischemic
attack, intermittent claudication and congestive heart
failure.
For prediction of 10-year risk of fatal cardiovascular
disease by the SCORE score estimation, risk factors were
used according to the algorithm reported by Conroy
et al. [11], including age, total cholesterol, systolic blood
pressure and smoking. Fatal cardiovascular disease was
defined as ICD-9 codes 798.1, 798.2, 401 through 414and 426 through 443, with the exception of the ICD-9
codes: 426.7, 429.0, 430.0, 432.1, 437.3, 437.4 and 437.5.
For prediction of global cardiovascular disease risk by
the Reynolds risk score we used cardiovascular risk fac-
tors according to the algorithm reported by Ridker et al.,
including systolic blood pressure, smoking, total choles-
terol, HDL cholesterol, hsCRP and a family history of
myocardial infarction < 60 years in first- degree relative
[16]. They defined global cardiovascular disease as inci-
dent myocardial infarction, stroke, coronary revasculari-
zation, or cardiovascular death.
Sample size and statistical analysis
Our power analysis was based on cardiovascular risk es-
timation based on the Framingham Heart Study [17].
Due to the young age of our participants, the estimated
absolute 10-year cardiovascular risk was likely to be low.
Therefore, our approach was to estimate the risk for
each woman as if the woman was 60 years old. This ap-
proach has been recommended in the cardiovascular
risk factor management guidelines for young women
with elevated risk factor levels [23]. For detecting an
estimated absolute 10-year cardiovascular risk difference
between women with a history of term gestational
hypertension or term preeclampsia (HTP) and women
with a history of normotensive pregnancies (NTP) of
10% increase after extrapolating to the age of 60, we
needed a sample size of 456 women for 80% power and
a 5% type 1 error probability (two sided), for inclusion in
3:1 ratio (3 HTP: 1 NTP). According to earlier studies
[28-30] we expected a homogeneous effect with low
prevalence of unfavorable cardiovascular risk factors in
normotensive term pregnancy women. Therefore, we
have used a 3:1 (HTP:NTP) inclusion ratio instead of 1:1
as we assumed that including more normotensive preg-
nancy women in 1:1 ratio would have no additional
value in this study as a result of homogeneous outcome
of cardiovascular risks.
Data were analyzed using SPSS software (version 20.0).
Baseline continuous data were expressed as means and
standard deviations or as medians and interquartile
ranges for not normally distributed values; dichotomous
data were presented as numbers and percentages. Com-
parison of continuous data with a skewed distribution was
performed using the non- parametric Mann–Whitney U
test and categorical data by the Chi-squared test. A
poisson regression analysis was performed to calculate
the incidence risk ratios and corresponding 95% confi-
dence intervals for the different cardiovascular risk esti-
mation categories. We made adjustments for potential
confounders, where appropriate, including parity (con-
tinuous variable) and current BMI (continuous vari-
able). For all tests, a p-value < 0.05 indicated statistical
significance.
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Between June 2008 and November 2010, a total of 300
women with a history of term gestational hypertension
or term preeclampsia and 94 women with a history of
normotensive term pregnancies were included in this
follow-up study. Of the eligible 751 women with a his-
tory of term gestational hypertension or term pre-
eclampsia, 168 women declined participation in the
follow-up study, 6 women refused blood drawing, 175
women were lost to follow-up, 101 women were preg-
nant or lactating and 1 woman had died in a car
accident.
At index pregnancy, women with term gestational
hypertension or term preeclampsia were more often nul-
liparous, had higher body mass index at the first ante-
natal visit, higher systolic and diastolic blood pressures
at the first antenatal visit, lower gestational age at deliv-
ery and lower birth weight compared with women with
a history of normotensive term pregnancies (Table 1). At
2.5 year follow-up women with a history of term gesta-
tional hypertension or term preeclampsia were more
often primiparous, used more antihypertensive medica-
tion, and had higher body mass index, higher systolic
and diastolic blood pressures and higher waist circum-
ferences compared with women with a history of
normotensive term pregnancy. There were no significant
differences in age, elapsed time since delivery and smok-
ing rates (Table 2).
Biochemical cardiovascular risk factors 2.5 years post-
partum, including glucose, HsCRP, total cholesterol,
HDL cholesterol and triglycerides, were all significantly
higher in women with a history of term gestational
hypertension or term preeclampsia compared withTable 1 Baseline characteristics at index pregnancy*
Characteristics H
Maternal age at delivery (years) 3




Systolic blood pressure at first antenatal visit (mmHg)‡ 12
Diastolic blood pressure at first antenatal visit (mmHg)‡ 7
BMI at first antenatal visit (kg/m2) 25.
Gestational age at delivery (weeks) 39.
Birth weight (gram) 3398
*Continuous data are expressed as median (IQR), dichotomous data as number of p
HTP women with a history of term gestational hypertension or term preeclampsia.
NTP women with a history of normotensive term pregnancies.
‡ = 38 HTP women (12%) had a systolic blood pressure of ≥ 140 mmHg or a diastol
antihypertensive medication).women with a history of normotensive term pregnancies
(Table 3).
Cardiovascular disease risk prediction
10-year general cardiovascular disease risk prediction by
the Framingham risk score
Figure 1 illustrates the risk percentages of developing
general cardiovascular disease within 10 years in women
with a history of term gestational hypertension or term
preeclampsia and women with a history of normotensive
term pregnancies at current age, calculated with the
Framingham risk score. At current age, 16 women (5%)
with a history of term gestational hypertension or term
preeclampsia had a 10-year general cardiovascular dis-
ease risk of > 5%, compared with no women (0%) with a
history of normotensive pregnancies, p=.02.
Figures 2A and B show the risk percentages of devel-
oping general cardiovascular disease within 10 years
(Figure 2A) and the different risk categories of the 10-
year prediction of developing general cardiovascular
disease calculated with the Framingham risk score
(Figure 2B) of hypertensive term pregnancy women and
normotensive term pregnancy women after extrapola-
tion of their age to 60 years. Poisson regression showed
that women with a history of term gestational hyperten-
sion or term preeclampsia, compared with women with
a history of normotensive term pregnancies, had a 2.5-
fold higher extrapolated risk of >5% (p<.001, IRR 2.5
95% CI (1.6 – 3.7)) and even an almost 6-fold higher ex-
trapolated risk of >10% (p=.001, IRR 5.8 95% CI (1.8 - 19))
to suffer from cardiovascular disease within 10-years.
After adjustment for parity and current BMI, women with
a history of term gestational hypertension or termTP cohort NTP cohort p value
(n=300) (n=94)
1 (28–35) 31 (28–34) .82
73 (89%) 94 (95%) .14
30 (10%) 5 (5%)
3 (1%) 0 (0%)
11 (69%) 30 (30%) < .001
0 (110–130) 110 (109–120) <.001
5 (68–80) 65 (60–70) <.001
2 (22.5-29.1) 22.7 (21.2-24.3) <.001
5 (38.4-40.2) 39.9 (39.3-40.7) .001
(3030–3710) 3693 (3216–3942) <.001
atients (%).
ic blood pressure of ≥ 90 mmHg at the first antenatal visit (without use of
Table 2 Outcome characteristics of the follow-up study, 2.5 years postpartum*
Characteristics HTP cohort NTP cohort p value
(n=300) (n=94)
Age at follow up (years) 34 (30–37) 34 (31–37) .80
Time elapsed since delivery (years) 2.4 (2.2-2.7) 2.5 (2.2-2.9) .54
Primiparous 134 (44%) 21 (22%) < .001
Smoking 60 (20%) 19 (19%) .82
BMI at follow up (kg/m2) 26.6 (23.8-30.5) 23.2 (21.8-25.5) <.001
Antihypertensive medication use 29 (10%) 0 (0%) .001
Hypertension 104 (35%) 1 (1%) <.001
Systolic blood pressure (mmHg) 124 (115–130) 110 (105–118) <.001
Diastolic blood pressure (mmHg) 80 (78–90) 74 (66–80) <.001
Family history of MI** < 60 years in first- degree relative 48 (16%) 11 (11%) .21
*Continuous data are expressed as median (IQR), dichotomous data as number of patients (%).
**MI Myocardial infarction.
HTP women with a history of term gestational hypertension or term preeclampsia.
NTP women with a history of normotensive term pregnancies.
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lar event risks of >5% (p<.001, IRR 2.3 95% CI (1.5 -
3.5)) and > 10% (p=.01, IRR 5.0 95% CI (1.6 - 16))
compared with women with a history of normotensive
term pregnancies.
30-year full cardiovascular disease risk prediction by
the Framingham risk score Figure 3A illustrates the
risk percentages of developing overall cardiovascular dis-
ease within 30 years in women with a history of term
gestational hypertension or term preeclampsia and
women with a history of normotensive term pregnancies
at current age, calculated with the Framingham risk
score. Figure 3B illustrates different risk categories of
the 30-year prediction of developing general cardiovas-
cular disease calculated with the Framingham risk score
at current age. Poisson regression analysis showed that
women with a history of term gestational hypertensionTable 3 Cardiovascular biomarkers in HTP women and
NTP women 2.5 years postpartum*
Cardiovascular
biomarker
HTP cohort NTP cohort p value
(n=300) (n=94)
Glucose, mg/dl 84.7 (81.1-91.9) 84.7 (79.3-88.3) .01
HsCRP, mg/l 2.2 (1.0-5.0) 0.9 (0.4-2.2) <.001
Total cholesterol,
mg/dl
181.8 (162.4-206.9) 177.9 (150.8-197.2) .02
HDL-cholesterol,
mg/dl
54.1 (46.4-61.9) 58.0 (50.3-65.8) .03
Triglycerides, mg/dl 80.6 (58.5-110.1) 62.9 (47.6-91.2) <.001
*Data are expressed as median (IQR).
HTP women with a history of term gestational hypertension or
term preeclampsia.
NTP women with a history of normotensive term pregnancies.or term preeclampsia, compared with women with a his-
tory of normotensive term pregnancies had an almost 3-
fold higher of >10% (p<.001, IRR 2.7 95% CI (1.6 – 4.5))
to suffer from cardiovascular disease within 30 years,
even after adjustment for parity and current BMI
(p=.002, IRR 2.4 95% CI (1.4 – 4.1)).Figure 1 10 - Year Framingham risk scores (%) of women with
a history of gestational hypertension or preeclampsia at term
(HTTP women closed bars) and women with a history of
uncomplicated normotensive pregnancies (NTP women, dotted
bars). The top and bottom of each box correspond to the 75th
percentile and 25th percentile, respectively. The whiskers (t bars) on
the top and botttom denote the 90th percentile and 10th
percentile, respectively.
Figure 2 10-year Framingham risk score extrapolated to the age of 60 years. A. 10-Year Framingham risk scores (%) extrapolated to the
age of 60 years of women with a history of uncomplicated normotensive pregnancies (NTP women, dotted bars). The top and bottom of each
box correspond to the 75th percentile and 25th percentile, respectively. The whiskers (t bars) on the top and botttom denote the 90th percentile
and 10th percentile, respectively. B. Division into 4 different risk categories (0 - 5%, >5% - 10%>10% - 20% and >20%). 10-Year risk of estimation
of overall cardiovascular disease risk according to the Framingham Heart Study algorithm based on the following risk factors, ie. age, smoking,
systolic blood pressure, HDL cholesterol, total cholesterol.
Figure 3 30-year Framingham risk score at current age. A. 30 - Year Framingham risk scores (%) at current age of women with a history of
gestational hypertension or preeclampsia at term (HTTP women closed bars) and women with a history of uncomplicated normotensive
pregnancies (NTP women, dotted bars). The top and bottom of each box correspond to the 75th percentile and 25th percentile, respectively. The
whiskers (t bars) on the top and botttom denote the 90th percentile and 10th percentile, respectively. B. Division into 4 different risk categories
(0 - 5%, >5% - 10%>10% - 20% and >20%). 30 - year risk of estimation of full cardiovascular disease risk by the Framingham Heart Study
algorithm based on the following risk factors, ie. age, smoking, systolic blood pressure, HDL cholesterol, total cholesterol, treatment for
hypertension and presence of diabetes.
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Table 4 Cardiovascular event risk prediction by the SCORE score and Reynolds risk score
Risk Prediction HTP Cohort (N=300) NTP Cohort (N=94) p value IRR (95% CI)
10-year fatal CVD risk prediction by the SCORE score (extrapolation to 60 years)
Mean (SD), % 1.2 (0.5) 1.1 (0.3) .02
Risk category 1% 242 (81%) 85 (90%)
Risk category 2% 48 (16%) 9 (10%)
Risk category 3% 9 (3%) 0 (0%)
Risk category 4% 1 (0.3%) 0 (0%)
10-year SCORE score risk >1% 58 (19%) 9 (10%) 2.0 (1.0 - 4.1)
10-year global CVD risk prediction by Reynolds risk score (extrapolation to 60 years)
Mean (SD), % 2.8 (2.1) 1.6 (1.1) .001
Risk category 1% 87 (29%) 60 (64%)
Risk category >1-5% 168 (56%) 30 (32%)
Risk category >5-10% 39 (13%) 4 (4%)
Risk category >10% 6 (2%) 0 (0%)
10-year Reynolds risk score risk > 5% 45 (15%) 4 (4%) 4.0 (1.0 - 17)
IRR incidence risk ratio.
CI confidence interval.
NTP women with a history of normotensive term pregnancies.
HTP women with a history of term gestational hypertension or term preeclampsia.
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by the SCORE score and 10-Year global cardiovascu-
lar disease risk prediction by the Reynolds risk score
Mean (SD) 10-year cardiovascular disease risk predictions
and different risk categories calculated by the SCORE
score and the Reynolds risk score are shown in Table 4.
Women with a history of term gestational hypertension or
term preeclampsia had significant higher mean risks cal-
culated by the SCORE score and the Reynolds risk score
compared with women with a history of normotensive
term pregnancies. Furthermore, women with a history of
term gestational hypertension or term preeclampsia were
more often represented in higher risk categories.Sub-analyses of the hypertensive term pregnancy co-
hort We divided the hypertensive term pregnancy co-
hort (n=300) in a primiparous subgroup (n=134, 44%)
and a multiparous subgroup (n=166, 56%) 2.5 years
postpartum. Furthermore, we subanalysed women with a
history of gestational hypertension at term (n=225, 75%)
and women with a history of preeclampsia at term
(n=75, 25%) and women with (n=93, 31%) or without
(n=207, 69%) severe gestational hypertension or severe
preeclampsia during their index pregnancy. No signifi-
cant differences were found between the subgroups in
the prevalence of hypertension 2.5 years postpartum,
biochemical cardiovascular risk factors 2.5 years postpar-
tum and in the estimated 10- and 30 year Framingham
cardiovascular event risks.Discussion
In this longitudinal follow-up study, we found that
women with a history of term gestational hypertension
or term preeclampsia have an increased 10-year cardio-
vascular disease risk at current age and after extrapolat-
ing the age to 60 years at least two years postpartum.
Furthermore, an increased 30-year cardiovascular risk at
current age was found in women with a history of term
gestational hypertension or term preeclampsia.Risk prediction models
Screening and treatment of cardiovascular disease should
target women at high risk rather than at women with a
single elevated risk factor [12]. Many risk prediction
models have been developed the last three decades to esti-
mate individual cardiovascular risk. The Framingham Risk
Score was the most influential multivariate risk predictor
of developing cardiovascular disease in the future and this
algorithm has been most often compared by other studies
[15,17,18,27]. The Reynolds Risk Score was developed in
women adding CRP and parental history of early myocar-
dial infarction before the age of 60 years as independent
risk variables in a female cohort [16] and reclassified 40%-
50% of women who were predicted by the Framingham
risk score [17] to be at intermediate risk into higher- or
lower risk categories. The SCORE equation has been vali-
dated for the European population and has been
recommended by the Third Joint European Task Force on
cardiovascular prevention in Europe [11]. This risk score
Hermes et al. BMC Pregnancy and Childbirth 2013, 13:126 Page 8 of 11
http://www.biomedcentral.com/1471-2393/13/126focuses at fatal total cardiovascular risk rather than at fatal
coronary heart disease. Other prediction models were
mostly designed and developed for men and therefore not
considered for this study. The QRISK score was developed
using a population- based clinical research database in
the UK incorporating ethnicity, deprivation and other
clinical conditions in the algorithm [13,14], resulting in
more accurate quantification of risks in south Asian
women compared to the Framingham risk score. How-
ever, participants in our study were predominantly Cau-
casian women and adding ethnicity to the risk estimate
was considered to have no additional value for risk esti-
mates. Therefore, we did not use the QRISK score for
our study. In 2012, Siontis et al. undertook a meta-
analysis to compare established risk prediction models
for cardiovascular disease [12]. They did not reach ro-
bust conclusions about the best risk prediction model
or the ranking of performance of different models. An
important question rises: which algorithm or model is
best suited for women with a history of hypertensive
pregnancy disorders at term to accurately estimate their
future cardiovascular risk? Unfortunately, we can not
answer this question with our present study results.
All four algorithms showed a significantly higher
risk in hypertensive term pregnancy women. This is
understandable, because the four scores are mostly
based on equivalent cardiovascular parameters and
these parameters were significantly higher in the
hypertensive term pregnancy cohort compared with
the normotensive term pregnancy cohort. However,
the definitions and cardiovascular endpoints between
the four risk prediction models differ. Only the Fra-
mingham Heart Study provides a 30-year risk predic-
tion model. This might be the most useful
prediction model for our relatively young study co-
hort, as age remains the most important parameter
in cardiovascular risk prediction models and extrapo-
lation is not necessary in this model for our rela-
tively young cohort. Furthermore, the Framingham
30-year risk score focuses at cardiovascular morbid-
ity and mortality rather than at cardiovascular mor-
tality alone (SCORE score), which seems important
in young women. Morbidity caused by non fatal car-
diovascular events is not only disabling for young
women, but it is also the major economic burden
for the health care system and society. Young
women might benefit from early screening and pre-
vention and it might be cost-effective. However, we
have to keep in mind that the longer the prediction
period, the less accurate the prediction will be for an
individual, as the nature of the design does not ac-
count for individual changes in risk factor levels that
could have taken place during the course of follow-
up [15].Comparison with other studies
Three other studies [29,31,32] previously assessed car-
diovascular risk scores in women with a history of
hypertensive pregnancy disorders. Fraser et al. [31]
reported significant higher mean Framingham 10-year
cardiovascular risks of 4.6% (0.15) in women with a his-
tory of gestational hypertension, 5.1% (0.41) in women
with a history of preeclampsia compared with 3.6%
(0.06) in women with a history without hypertensive
pregnancy disorders. These risks were higher compared
with the 10-year cardiovascular risks (at current age) in
our study in women with a history of hypertensive preg-
nancy disorders. This might be explained by two
differences.
First, Fraser et al. included not only women with a his-
tory of hypertensive pregnancy disorders at term but
also women with a history of preterm hypertensive preg-
nancy disorders, which are known for their higher risk
of cardiovascular disease later. Second, the follow-up
period of 18 years by Fraser et al. was longer compared
with our follow-up period of 2.5 years, which resulted in
a significant age difference between the two studies and,
per definition, in lower estimation of cardiovascular risk
in our study. Smith et al. [29,32] reported comparable
10-year cardiovascular event risks as our study. How-
ever, they included women with a history of both pre-
term and term preeclampsia and they had a shorter
follow-up period of 1 year.
Mongraw-Chaffin et al. [33] prospectively investigated
the contribution of hypertensive pregnancy complica-
tions on the risk of cardiovascular disease death. They
found that women with a history of preeclampsia with
onset after 34 weeks’ gestation, after a follow-up period
of 30 years and with a median age of 56 years, had a cu-
mulative cardiovascular disease death survival of 98.3%
and women without a history of preeclampsia had a car-
diovascular death survival of 99.3%. We calculated a
mean 10-year fatal cardiovascular disease risk of 1.2%
(0.5) in our hypertensive term pregnancy cohort after
extrapolating the age of each participant to 60 years.
This is a slightly lower risk compared with the 1.7% car-
diovascular death risk published by Mograw-Chaffin
et al. An explanation might be that Mongraw-Chaffin
studied women with preeclampsia who delivered after
34 weeks’ gestation, while we included women with both
gestational hypertension and preeclampsia after 36
weeks’ gestation. These differences in both gestational
age and hypertensive disorder might explain the small
discrepancy between the risks. A second explanation
might be that hypertensive pregnancy disorders are inde-
pendent risk factors for cardiovascular disease later in
life and as a consequence current cardiovascular risk
prediction models underestimate women’s cardiovascu-
lar disease risks, as obstetric history is not included as a
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ies have to evaluate whether hypertensive pregnancy
disorders have to be included as an independent vari-
able in cardiovascular risk prediction models for
women to improve their assessment of reliable car-
diovascular risk estimation for the long term CVD
outcome.
Strengths and limitations
The major strength of this longitudinal follow-up study
is that we used a unique prospective cohort from a ran-
domized controlled trial, which consisted of women with
a history of term gestational hypertension or term pre-
eclampsia. Hypertensive pregnancy disorders at term are
common disorders and therefore of great interest for
health care providers. These disorders may be used as a
discriminating test whether or not the clinician has to
screen for cardiovascular risk factors and calculate sub-
sequent individual cardiovascular risk.
This study has also potential limitations. First, due to
the young age of our study participants, 10-year overall
cardiovascular disease risk in our cohort was < 5% in all
normotensive term pregnancy women and in 95% of
hypertensive term pregnancy women in the Framingham
Risk Score. For this reason we extrapolated the risk to
an age of 60 years. Between current age and the age of
60 years, individual cardiovascular risk factors might
change over time. In our study, risk factors were deter-
mined at a relatively young age and extrapolation of the
age does not account for possible changes in risk factors
over time. However, our study method seems an appro-
priate method considering that both charts of 10 - year
prediction after extrapolation to 60 years and charts of
30-year prediction at current age show similar effects.
Second, we performed a cohort study, in which preg-
nancy data of women with a history of gestational hyper-
tension or preeclampsia were collected at baseline while
index pregnancy data of normotensive term pregnancy
women were reviewed in detail from medical records at
the time of inclusion in the study. However, the informa-
tion on pregnancy data addressed in this manuscript was
nearly all complete in the medical charts.
Third, due to refusal to participate in the follow-up
study, pregnant and lactating women at the time of
follow-up, and women who were lost to follow-up, we
were not able to include the total of 342 women with a
history of gestational hypertension or term preeclampsia
as described in our power analysis.
Finally, all normotensive term pregnancy women had
one or more uncomplicated pregnancies, which might
have resulted in a “cardiovascular healthier” cohort com-
pared with a population based cohort and subsequently
this relative healthy cohort might have resulted in over-
estimation of the effect in women with a history of termgestational hypertension or term preeclampsia. However,
the mean 10-year cardiovascular disease risk in the
Framingham risk study in women of 60 years was 6.4%.
The mean extrapolated 10-year cardiovascular disease
risk of women with a history of term gestational hyper-
tension or term preeclampsia was higher, namely 7.2%.
Assuming that levels of cardiovascular risk factors in
women with a history of term gestational hypertension
or term preeclampsia, without intervention or preven-
tion, will worsen over time until the age of 60, the real
estimated 10-year cardiovascular risk at the age of
60 years of women with a history of term gestational
hypertension or term preeclampsia may be even higher
than our reported 7.2%. Thus, even without comparison
with women with a history of normotensive term preg-
nancies, a mean 10-year cardiovascular event risk of 7%
is of interest for physicians, as it is a higher risk com-
pared with the reported risk of the population based co-
hort of the Framingham Heart Study.
Conclusions
In conclusion, women with a history of gestational
hypertension or preeclampsia at term have higher (ex-
trapolated) 10-year cardiovascular event risks and 30-
year cardiovascular event risks compared with women
with a history of uncomplicated pregnancies. Our study
results strongly suggest that women with a history of
hypertensive pregnancy disorders at term may be offered
screening and counseling for cardiovascular risk factors
after their pregnancy to calculate and estimate cardio-
vascular event risks.
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